Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group.
Mourksi NE, Dalban C, Colombe-Vermorel A, Odeyer L, Simioni V, Frenel JS, Fabbro M, Bazan F, Abadie-Lacourtoisie S, Coquan E, Martinez S, Garin G, Tabone-Eglinger S, Treilleux I, Chabaud S, Pérol D, Ray-Coquard I, Heudel PE, Diaz JJ, Marcel V.
Mourksi NE, et al. Among authors: dalban c.
Mol Oncol. 2023 Jan;17(1):27-36. doi: 10.1002/1878-0261.13340. Epub 2022 Dec 7.
Mol Oncol. 2023.
PMID: 36370117
Free PMC article.